Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 16, 2007 Brian Lawler	MedImmune's Improved Flu Vaccine One of the three most important traits for a drug's success is convenience in dosing, so investors should be mindful of the FDA's actions on FluMist, MedImmune's nasal spray vaccine, in the coming months.
The Motley Fool March 1, 2004 Alyce Lomax	MedImmune Under the Weather After short-term setbacks, the biotech turns to the long term.
The Motley Fool November 29, 2007 Brian Lawler	Another Chapter in Glaxo's Relenza Saga An FDA advisory panel suggested that the Relenza label should be strengthened to include the possibility of abnormal behavior and hallucinations in those who take it.
The Motley Fool July 28, 2010 Brian Orelli	Amplifying the Risk-Reward Ratio Amplify, Medtronic's latest, gets a mixed reaction at FDA advisory panel meeting.
The Motley Fool July 29, 2010 Brian Orelli	This FDA Panel Isn't Brilliant Why does AstraZeneca's blood thinner Brilinta work better outside the U.S. than here at home? The Food and Drug Administration's advisory panel didn't seem to have a good explanation, but they didn't appear to care much, either.
The Motley Fool June 16, 2004 Alyce Lomax	It's Half-Time at MedImmune The company will slash the price of FluMist.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
The Motley Fool April 29, 2004 Charly Travers	MedImmune's Big Gamble FluMist may not be worth the gigantic R&D investment.
The Motley Fool March 19, 2007 Brian Lawler	Is Dendreon Doomed? A pivotal FDA regulatory meeting approaches for the development-stage pharma. Investors, take note.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
The Motley Fool May 30, 2007 Brian Orelli	MedImmune's FDA Roller Coaster The vaccine maker is having its share of ups and downs, courtesy of the FDA. Investors, take note.
The Motley Fool May 13, 2011 Brian Orelli	FDA Advisory Panel Positive! Shares Punished. Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved.
The Motley Fool June 11, 2010 Brian Orelli	25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool August 21, 2008 Brian Orelli	Johnson & Johnson Gets Rejected The FDA rejects Johnson & Johnson's bid to expand the label of its antibiotic.
The Motley Fool October 30, 2006 Brian Lawler	MedImmune's Mediocre Quarter Some patient folks may be willing to wait on MedImmune to turn things around and justify its high valuation, but most other investors should be able to find better value elsewhere in the biotech industry.
The Motley Fool September 16, 2010 Brian Orelli	Abbott's Product Line May Get Thinner Not that it needs the obesity drug.
The Motley Fool July 15, 2010 Brian Orelli	The Blockbuster Drug Survives Another Body Blow Avandia is still standing.
The Motley Fool January 13, 2004 Alyce Lomax	MedImmune's Sticker Shock Price cut for FluMist is reportedly in the works.
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool March 10, 2010 Brian Orelli	Up 160% With Room to Run You've got to love biotech and InterMune.
The Motley Fool March 19, 2009 Brian Orelli	One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today
Chemistry World July 16, 2010 Matt Wilkinson	Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool April 1, 2011 Travis Hoium	Optimer Pharmaceuticals Shares Popped: What You Need to Know Shares of Optimer Pharmaceuticals jumped 12% today after positive news from the FDA was released.
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool July 20, 2006 Brian Lawler	MedImmune Is Easy to Resist Despite the prospects from sales of two new vaccines, it's hard to feel better about this stock.
The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: MedImmune Will the years ahead continue to be positive for the biopharma? Next year's guidance is for revenue to grow 15% over the $1.3 billion that is expected in 2006. Investors should watch to make sure this is possible.
The Motley Fool September 14, 2010 Brian Orelli	42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason.
The Motley Fool April 2, 2009 Brian Orelli	A Diabetic Compromise Bristol-Myers and AstraZeneca will have to test their drug after it goes on the market.
BusinessWeek March 29, 2004 Gene G. Marcial	Recovery At MedImmune? Flu season is over, but it was a disaster for the No. 6 U.S. biotech, MedImmune (MEDI ). Its ballyhooed FluMist, a nasal-spray flu vaccine, was a flop -- which sent the stock reeling, from 42 in June to 23 now. As a result, some pros are buying: David Katz of Matrix Asset Advisors is confident MedImmune can turn FluMist around, by pricing it lower and educating doctors and consumers about the product.
The Motley Fool October 5, 2004 Alyce Lomax	No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season.
The Motley Fool August 18, 2010 Brian Orelli	More Pain Ahead for Eli Lilly? An advisory panel meeting tomorrow could further the company's slide.
The Motley Fool June 8, 2010 Brian Orelli	Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA.
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool August 10, 2010 Brian Orelli	When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.
The Motley Fool September 10, 2008 Brian Lawler	A Pfizer Drug With a Cloudy Future The company offers another drug with mixed odds to the FDA.
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
The Motley Fool June 15, 2007 Brian Orelli	Get Your Uncle to Pay for Your Capital Improvements MedImmune and Sanofi-Aventis recently announced that they had convinced the U.S. government to pick up a majority of the tabs to renovate their plants. There aren't too many industries where you can invest in companies that get free money from the government.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool August 18, 2010 Brian Orelli	No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals
The Motley Fool July 27, 2010 Brian Orelli	Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant.
The Motley Fool November 12, 2010 Brian Orelli	Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week.